3 completed, 2 active not recruiting, 1 suspended. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 2, Suspended 1 |
| Phase 1 | 1 | Suspended 1 |
Follow CD20 Positive: new trials by email Literature Review of CD20 Positive trials Research Report on CD20 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Acalabrutinib, Venetoclax - Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2019-08-13 | 2026-08-10 |
| Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab - Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Suspended | Northwestern University | 30 | 2018-11-20 | 2022-08-15 |
| Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 48 | 2016-04-11 | 2024-09-24 |
| Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Rituximab - CCND1 Positive, CCND2 Positive | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 113 | 2013-07-15 | 2026-07-08 |
| Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission | Phase 2 | Completed | M.D. Anderson Cancer Center | 72 | 2011-07-12 | 2021-05-03 |
| Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bortezomib - CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2007-02-13 | 2019-09-10 |
Lymphoma, Mantle-Cell (2) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Hematologic Diseases (2) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Herpesviridae Infections (1) · Infections (1) · Leukemia (1)
CT-P10 (4) · Rituximab (4) · Cyclophosphamide (2) · Cytarabine (2) · Doxorubicin (2) · Methotrexate (2) · Vincristine (2) · ibrutinib (2) · merphos (2) · Antilymphocyte Serum (1) · Bortezomib (1) · Calcium Dobesilate (1) · Carmustine (1) · Dexamethasone (1) · Etoposide (1)
M.D. Anderson Cancer Center (5) · Northwestern University (1)
United States (6)
Elias Jabbour (1) · Issa Khouri (1) · Loretta J Nastoupil (1) · Michael L Wang, MD (1) · Reem Karmali, MD (1)
PMID 26640039, PMID 32589978, PMID 34138471, PMID 34797699, PMID 35622074, PMID 37985359, PMID 40706069
P30CA016672 (1), P30CA060553 (1)